Through Omada’s GLP-1 Flex Care offering, employers gain a new flexible option to connect employees with anti-obesity medication, virtual care, and lifestyle support
Omada Health has announced the launch of GLP-1 Flex Care, a new healthcare solution designed to help employers expand access to GLP-1 medications for obesity management while maintaining control over rising healthcare costs. The announcement marks a significant development in virtual healthcare services, AI-enabled patient care models, and modern obesity treatment strategies that combine medical oversight with personalized lifestyle support.
GLP-1 medications have rapidly gained demand among employees seeking effective weight management and metabolic health solutions. However, many employers face financial barriers when attempting to fully cover these medications through traditional healthcare benefits. Omada Health’s GLP-1 Flex Care program addresses this challenge by allowing employees to purchase medications independently through cash-pay channels while still receiving structured clinical guidance, prescribing support, and continuous care coordination.
Health Technology Insights: https://healthtechnologyinsights.com/patient-trust-first-the-rise-of-ethical-health-tech/
Through this model, employers can provide access to medically supervised obesity treatment without assuming the full financial burden of medication costs. The program enables employees to undergo clinical evaluations, receive prescriptions for FDA-approved GLP-1 medications, and access ongoing medical oversight throughout their treatment journey.
Wei-Li Shao, President of Omada Health, emphasized that the program was designed to balance employee health needs with employer budget constraints. He noted that employers should not have to choose between providing obesity care and protecting their financial sustainability. GLP-1 Flex Care offers a practical solution that enables organizations to support employee health outcomes while maintaining control over healthcare spending.
The program provides a comprehensive virtual care framework that includes laboratory testing, medication titration management, side effect monitoring, nutrition guidance, and physical activity counseling. Providers within the program also help members identify the most appropriate medication options – whether injectable or oral formulations – based on clinical profiles and affordability considerations.
Importantly, GLP-1 Flex Care builds upon Omada Health’s established virtual care model, which integrates medical oversight with personalized coaching and behavior change support. This integrated approach aims to improve long-term outcomes by addressing both the clinical and lifestyle aspects of obesity management.
Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health, highlighted the importance of comprehensive care when prescribing GLP-1 medications. According to Tsang, research shows that patients who receive structured clinical support alongside medication therapy demonstrate higher medication adherence and improved weight loss outcomes. Additionally, evidence suggests that participants in Omada’s program maintain weight loss even after discontinuing medication, underscoring the value of sustainable lifestyle intervention.
The launch of GLP-1 Flex Care reflects Omada Health’s broader strategy of offering flexible healthcare benefit solutions that align with diverse employer coverage models. As demand for GLP-1 therapies continues to grow across healthcare systems, employers are increasingly seeking scalable solutions that balance access, affordability, and measurable patient outcomes.
GLP-1 Flex Care will become available to employers later in 2026, further expanding Omada Health’s portfolio of obesity care solutions that combine clinical expertise, virtual care delivery, and patient-centered health management.
Health Technology Insights: https://healthtechnologyinsights.com/the-patient-journey-problem-that-healthcare-technology-must-solve/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
